Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations

Critical Reviews in Oncology/Hematology

Volumn 60, Issue 1, 2006, Pages 9-18

  Verma, Mukesh ^a   Manne, Upender ^b  

^a Cancer Control and Population Sciences   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Biomarker; Epigenetics; Risk Assessment; Screening

Indexed keywords

CA 125 ANTIGEN; DEATH ASSOCIATED PROTEIN KINASE; K RAS PROTEIN; MITOCHONDRIAL DNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CHROMOSOME DELETION; COLORECTAL CANCER; CPG ISLAND; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; DNA METHYLATION; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; EXCISION REPAIR; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENE SILENCING; GENE TRANSLOCATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HETEROZYGOSITY LOSS; HIGH RISK POPULATION; HUMAN; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MICROSATELLITE INSTABILITY; MOUTH CANCER; ONCOGENE; PANCREAS CANCER; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; RISK FACTOR; STOMACH CANCER; THYROID CANCER; UTERINE CERVIX CANCER;

EID: 33748470485     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2006.04.002     Document Type: Review

References (90)

1. Shih I.M., Zhou W., Goodman S.N., Lengauer C., Kinzler K.W., and Vogelstein B. Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. Cancer Res 61 3 (2001) 818-822
2. Landis S.H., Murray T., Bolden S., and Wingo P.A. Cancer Statistics. CA J Clin 49 1 (1999) 8-31
3. Neumann A.S., Sturgis E.M., and Wei Q. Nucleotide excision repair as a marker for susceptibility to tobacco-related cancers: a review of molecular epidemiological studies. Mol Carcinog 42 2 (2005) 65-92
4. Winawer S.J. Screening of colorectal cancer: progress and problems. Recent Results Cancer Res 166 (2005) 231-244
5. Osborn N.K., and Ahlquist D.A. Stool screening for colorectal cancer: molecular approaches. Gastroenterology 128 1 (2005) 192-206
6. Ahlquist D.A. Colorectal cancer prevention and detection. Introduction. Gastroenterol Clin North Am 31 4 (2002) xi-xii
7. Li Y.L., Tian Z., Wu D.Y., Fu B.Y., and Xin Y. Loss of heterozygosity on 10q23 3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions. World J Gastroenterol 11 2 (2005) 285-288
8. Salto-Tellez M., Tan S.Y., Chiu L.L., and Koay E.S. Dinucleotide microsatellite repeats are essential for the diagnosis of microsatellite instability in colorectal cancer in Asian patients. World J Gastroenterol 11 18 (2005) 2781-2783
9. Chang S.C., Lin J.K., Lin T.C., and Liang W.Y. Loss of heterozygosity: an independent prognostic factor of colorectal cancer. World J Gastroenterol 11 6 (2005) 778-784
10. Ito Y., Yoshida H., Tomoda C., et al. HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma. Anticancer Res 25 1A (2005) 179-182
11. Kumimoto H., Yamane Y., Nishimoto Y., et al. Frequent somatic mutations of mitochondrial DNA in esophageal squamous cell carcinoma. Int J Cancer 108 2 (2004) 228-231
12. Jeronimo C., Nomoto S., Caballero O.L., et al. Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene 20 37 (2001) 5195-5198
13. Esteller M., Sanchez-Cespedes M., Rosell R., Sidransky D., Baylin S.B., and Herman J.G. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59 1 (1999) 67-70
14. Goessl C., Muller M., Straub B., and Miller K. DNA alterations in body fluids as molecular tumor markers for urological malignancies. Eur Urol 41 6 (2002) 668-676
15. Lee T.L., Leung W.K., Chan M.W., et al. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res 8 6 (2002) 1761-1766
16. Sanchez-Cespedes M., Esteller M., Wu L., et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 60 4 (2000) 892-895
17. Usadel H., Brabender J., Danenberg K.D., et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 62 2 (2002) 371-375
18. Seng T.J., Ichimura K., Liu L., Tingby O., Pearson D.M., and Collins V.P. Complex chromosome 22 rearrangements in astrocytic tumors identified using microsatellite and chromosome 22 tile path array analysis. Gene Chromosome Cancer 43 2 (2005) 181-193
19. Wada K., Maruno M., Suzuki T., et al. Chromosomal and genetic aberrations differ with meningioma subtype. Brain Tumor Pathol 21 3 (2004) 127-133
20. Hartmann C., Mueller W., Lass U., Kamel-Reid S., and von Deimling A. Molecular genetic analysis of oligodendroglial tumors. J Neuropathol Exp Neurol 64 1 (2005) 4-10
21. Davies R.J., Miller R., and Coleman N. Colorectal cancer screening: prospects for molecular stool analysis. Nat Rev Cancer 5 3 (2005) 199-209
22. Wang Z., Cummins J.M., Shen D., et al. Three classes of genes mutated in colorectal cancers with chromosomal instability. Cancer Res 64 9 (2004) 2998-3001
23. Arends J.W. Molecular interactions in the Vogelstein model of colorectal carcinoma. J Pathol 190 4 (2000) 412-416
24. He T.C., Sparks A.B., Rago C., et al. Identification of c-MYC as a target of the APC pathway. Science 281 5382 (1998) 1509-1512
25. Fitzgerald R.C. Genetics and prevention of oesophageal adenocarcinoma. Recent Results Cancer Res 166 (2005) 35-46
26. Metzger R., Schneider P.M., Warnecke-Eberz U., Brabender J., and Holscher A.H. Molecular biology of esophageal cancer. Onkologie 27 2 (2004) 200-206
27. Wang Q.H., Zhang P.H., Li G., Cong J., and Hu N. [Loss of heterozygosity in esophageal squamous cell carcinoma and its precursor lesion]. Zhonghua Bing Li Xue Za Zhi 33 4 (2004) 346-349
28. Garza-Gonzalez E., Bosques-Padilla F.J., El-Omar E., et al. Role of the polymorphic IL-1B IL-1RN and TNF-A genes in distal gastric cancer in Mexico. Int J Cancer 114 2 (2005) 237-241
29. Dai Y.C., Ho C.L., Tsai Y.C., et al. Allelic loss of 14q32 in the pathogenesis of gastrointestinal and ampullary malignancies: mapping of the target region to a 17 cM interval. J Cancer Res Clin Oncol 131 2 (2005) 94-100
30. Gologan A., Graham D.Y., and Sepulveda A.R. Molecular markers in Helicobacter pylori-associated gastric carcinogenesis. Clin Lab Med 25 1 (2005) 197-222
31. Perez R.O., Jacob C.E., D'Ottaviano F.L., et al. Microsatellite instability in solitary and sporadic gastric cancer. Rev Hosp Clin Fac Med Sao Paulo 59 5 (2004) 279-285
32. Wang J.Y., Hsieh J.S., Chen C.C., et al. Alterations of APC, c-met, and p53 genes in tumor tissue and serum of patients with gastric cancers. J Surg Res 120 2 (2004) 242-248
33. Yousef G.M., Obiezu C.V., Luo L.Y., et al. Human tissue kallikreins: from gene structure to function and clinical applications. Adv Clin Chem 39 (2005) 11-79
34. Obiezu C.V., and Diamandis E.P. Human tissue kallikrein gene family: applications in cancer. Cancer Lett 224 1 (2005) 1-22
35. Hoefling C., Schmidt H., Meinhardt M., et al. Comparative evaluation of microsatellite marker AP-PCR and CGH studies in primary renal cell carcinoma. Int J Mol Med 13 6 (2004) 835-842
36. Smith M.T., McHale C.M., Wiemels J.L., et al. Molecular biomarkers for the study of childhood leukemia. Toxicol Appl Pharmacol 206 2 (2005) 237-245
37. Fleury I., Primeau M., Doreau A., et al. Polymorphisms in genes involved in the corticosteroid response and the outcome of childhood acute lymphoblastic leukemia. Am J Pharmacogenomics 4 5 (2004) 331-341
38. Moinzadeh P., Breuhahn K., Stutzer H., and Schirmacher P. Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade - results of an explorative CGH meta-analysis. Br J Cancer 92 5 (2005) 935-941
39. Nakajima T., Moriguchi M., Mitsumoto Y., et al. Centrosome aberration accompanied with p53 mutation can induce genetic instability in hepatocellular carcinoma. Mod Pathol 17 6 (2004) 722-727
40. Mao L. Molecular abnormalities in lung carcinogenesis and their potential clinical implications. Lung Cancer 34 Suppl. 2 (2001) S27-S34
41. Sugio K., Kishimoto Y., Virmani A.K., Hung J.Y., and Gazdar A.F. K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res 54 22 (1994) 5811-5815
42. Haga Y., Hiroshima K., Iyoda A., et al. Frequency of loss of heterozygosity at 3 p, 9 p, 13 q, and 17 p is related to proliferative activity in smokers with stage I non-small cell lung cancer. Thorac Cardiovasc Surg 53 2 (2005) 114-117
43. Pan H., Califano J., Ponte J.F., et al. Loss of heterozygosity patterns provide fingerprints for genetic heterogeneity in multistep cancer progression of tobacco smoke-induced non-small cell lung cancer. Cancer Res 65 5 (2005) 1664-1669
44. Sonobe M., Manabe T., Wada H., and Tanaka F. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer 93 3 (2005) 355-363
45. Vineis P., Veglia F., Anttila S., et al. CYP1A1 GSTM1 and GSTT1 polymorphisms and lung cancer: a pooled analysis of gene-gene interactions. Biomarkers 9 3 (2004) 298-305
46. Lee H.C., Yin P.H., Lin J.C., et al. Mitochondrial genome instability and mtDNA depletion in human cancers. Ann N Y Acad Sci 1042 (2005) 109-122
47. Jakupciak J.P., Wang W., Markowitz M.E., et al. Mitochondrial DNA as a cancer biomarker. J Mol Diagn 7 2 (2005) 258-267
48. Tammela J., and Odunsi K. Gene expression and prognostic significance in ovarian cancer. Minerva Ginecol 56 6 (2004) 495-502
49. Otsuka J., Okuda T., Sekizawa A., et al. Detection of p53 mutations in the plasma DNA of patients with ovarian cancer. Int J Gynecol Cancer 14 3 (2004) 459-464
50. Verma M. Pancreatic cancer epidemiology. Technol Cancer Res Treat 4 3 (2005) 295-301
51. Linja M.J., and Visakorpi T. Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol 92 4 (2004) 255-264
52. Harkonen P., Kyllonen A.P., Nordling S., and Vihko P. Loss of heterozygosity in chromosomal region 16q24 3 associated with progression of prostate cancer. Prostate 62 3 (2005) 267-274
53. Mattos Dos Santos R., Aparecida Rainho C., Carlos Souza Trindade J., Carlos Souza Trindade Filho J., Lauro Viana De Camargo J., and Regina Rogatto S. Genotyping of AR and PSA polymorphisms in a patient with Klinefelter syndrome, non-Hodgkin lymphoma, and adenocarcinoma of the prostate. Cancer Genet Cytogenet 153 2 (2004) 165-169
54. Heinlein C.A., and Chang C. Androgen receptor in prostate cancer. Endocr Rev 25 2 (2004) 276-308
55. Boyle P., Severi G., and Giles G.G. The epidemiology of prostate cancer. Urol Clin North Am 30 2 (2003) 209-217
56. Haiman C.A., Brown M., Hankinson S.E., et al. The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study. Cancer Res 62 4 (2002) 1045-1049
57. Li W., Cavasotto C.N., Cardozo T., et al. Androgen receptor mutations identified in prostate cancer and androgen insensitivity syndrome display aberrant ART-27 coactivator function. Mol Endocrinol 19 9 (2005) 2273-2282
58. Sato T., Harao M., Nakano S., Jotsuka T., Suda N., and Yamashita J. Circulating tumor cells detected by reverse transcription-polymerase chain reaction for carcinoembryonic antigen mRNA: distinguishing follicular thyroid carcinoma from adenoma. Surgery 137 5 (2005) 552-558
59. Jones P.A. Overview of cancer epigenetics. Semin Hematol 42 3 Suppl. 2 (2005) S3-S8
60. Toyooka S., Toyooka K.O., Maruyama R., et al. DNA methylation profiles of lung tumors. Mol Cancer Ther 1 1 (2001) 61-67
61. Lowenfels A.B., and Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 20 2 (2006) 197-209
62. Feinberg A.P. The epigenetics of cancer etiology. Semin Cancer Biol 14 6 (2004) 427-432
63. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 5 3 (2005) 223-231
64. Kawakami T., Okamoto K., Ogawa O., and Okada Y. XIST unmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer. Lancet 363 9402 (2004) 40-42
65. Tada Y., Wada M., Taguchi K., et al. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res 62 14 (2002) 4048-4053
66. Rousseau E., Ruchoux M.M., Scaravilli F., et al. CDKN2A CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. Neuropathol Appl Neurobiol 29 6 (2003) 574-583
67. Kuerbitz S.J., Pahys J., Wilson A., Compitello N., and Gray T.A. Hypermethylation of the imprinted NNAT locus occurs frequently in pediatric acute leukemia. Carcinogenesis 23 4 (2002) 559-564
68. Muller H.M., Fiegl H., Widschwendter A., and Widschwendter M. Prognostic DNA methylation marker in serum of cancer patients. Ann N Y Acad Sci 1022 (2004) 44-49
69. Kalantari M., Calleja-Macias I.E., Tewari D., et al. Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia. J Virol 78 23 (2004) 12762-12772
70. Jakubickova L., Barathova M., Pastorekova S., Pastorek J., and Gibadulinova A. Expression of S100P gene in cervical carcinoma cells is independent of E7 human papillomavirus oncogene. Acta Virol 49 2 (2005) 133-137
71. Wiley D.J., Huh J., Rao J.Y., et al. Methylation of human papillomavirus genomes in cells of anal epithelia of HIV-infected men. J Acquir Immune Defic Syndr 39 2 (2005) 143-151
72. Cui H., Cruz-Correa M., Giardiello F.M., et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299 5613 (2003) 1753-1755
73. Pegg A.E. Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res 462 2-3 (2000) 83-100
74. Shen L., Kondo Y., Rosner G.L., et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 97 18 (2005) 1330-1338
75. Thorstensen L., Lind G.E., Lovig T., et al. Genetic and epigenetic changes of components affecting the WNT pathway in colorectal carcinomas stratified by microsatellite instability. Neoplasia 7 2 (2005) 99-108
76. Takahashi T., Shigematsu H., Shivapurkar N., et al. Aberrant promoter methylation of multiple genes during multistep pathogenesis of colorectal cancers. Int J Cancer 118 4 (2006) 924-931
77. Fiegl H., Gattringer C., Widschwendter A., et al. Methylated DNA collected by tampons--a new tool to detect endometrial cancer. Cancer Epidemiol Biomarkers Prev 13 5 (2004) 882-888
78. Martini M., Ciccarone M., Garganese G., et al. Possible involvement of hMLH1, p16(INK4a) and PTEN in the malignant transformation of endometriosis. Int J Cancer 102 4 (2002) 398-406
79. Yoshikawa H., Matsubara K., Qian G.S., et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 28 1 (2001) 29-35
80. Lofton-Day C., and Lesche R. DNA methylation markers in patients with gastrointestinal cancers. Current understanding, potential applications for disease management and development of diagnostic tools. Dig Dis 21 4 (2003) 299-308
81. Ishida E., Nakamura M., Ikuta M., et al. Promotor hypermethylation of p14(ARF) is a key alteration for progression of oral squamous cell carcinoma. Oral Oncol 41 6 (2005) 614-622
82. Li L.C., Carroll P.R., and Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 97 2 (2005) 103-115
83. Henrique R., Jeronimo C., Hoque M.O., et al. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions. DNA Cell Biol 24 4 (2005) 264-269
84. Bremnes R.M., Sirera R., and Camps C. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?. Lung Cancer 49 1 (2005) 1-12
85. Garcia-Olmo D.C., Gutierrez-Gonzalez L., Ruiz-Piqueras R., Picazo M.G., and Garcia-Olmo D. Detection of circulating tumor cells and of tumor DNA in plasma during tumor progression in rats. Cancer Lett 217 1 (2005) 115-123
86. Xie G.S., Hou A.R., Li L.Y., Gao Y.N., and Cheng S.J. Quantification of plasma DNA as a screening tool for lung cancer. Chin Med J (Engl) 117 10 (2004) 1485-1488
87. Gillespie K.M., Valovin S.J., Saunby J., et al. HLA class II typing of whole genome amplified mouth swab DNA. Tissue Antigens 56 6 (2000) 530-538
88. Adkins K.K., Strom D.A., Jacobson T.E., Seemann C.R., O'Brien D.P., and Heath E.M. Utilizing genomic DNA purified from clotted blood samples for single nucleotide polymorphism genotyping. Arch Pathol Lab Med 126 3 (2002) 266-270
89. Sjoholm M.I., Hoffmann G., Lindgren S., Dillner J., and Carlson J. Comparison of archival plasma and formalin-fixed paraffin-embedded tissue for genotyping in hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 14 1 (2005) 251-255
90. Sun G., Kaushal R., Pal P., et al. Whole-genome amplification: relative efficiencies of the current methods. Leg Med (Tokyo) 7 5 (2005) 279-286